Skip to main content
Hereditary Cancer in Clinical Practice logoLink to Hereditary Cancer in Clinical Practice
. 2018 May 2;16:10. doi: 10.1186/s13053-018-0093-1

Retraction Note to: The BRCA2 variant c.68–7 T > A is associated with breast cancer

Pål Møller 1,2,3,, Eivind Hovig 2,4,5
PMCID: PMC5930441  PMID: 29745381

Retraction

This article [1] has been retracted at the request of the authors. Upon re-review of the data, the authors identified coding errors in this study. Due to an error in the SQL query, the conclusions drawn in the article are incorrect. A re-examination of the data shows that there is no association between familial breast cancer and the BRCA2 variant c.68–7 T > A. Another recent study suggests that the variant is not pathogenic [2]. All authors agree to this retraction.

Footnotes

The online version of the original article can be found at http://dx.doi.org/10.1186/s13053-017-0080-y.

References

  • 1.Møller P, et al. The BRCA2 variant c.68-7 T>a is associated with breast cancer. Hered Cancer Clin Pract. 2017;15:20. doi: 10.1186/s13053-017-0080-y. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 2.Colombo M, et al. The BRCA2 c.68-7T > a variant is not pathogenic: a model for clinical calibration of spliceogenicity. Hum Mutat. 2018;39:729–741. doi: 10.1002/humu.23411. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Hereditary Cancer in Clinical Practice are provided here courtesy of BMC

RESOURCES